Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Stabilizing pharmaco-active Membrane proteins with Zwitterionic polymers and leveraging Surface Plasmon Resonance as an Analytical platform

ZwitterMPs

Membrane proteins, particularly G-protein-coupled receptors (GPCRs), represent 25-30% of current drug targets. Among them, metabotropic glutamate receptor (mGluR), a Class C and group 1 type GPCR, is emerging as an attractive therapeutic target for various neurological and psychiatric disorders such as Alzheimer’s disease, Parkinson's disease...

Funding Programme
Start Date
End Date
Total Funding
€ 207 758
European Countries Involved

STED-enabled super-resolution multimode-fibre based holographic endoscopy for deep-tissue observations of neuronal connectivity

STEDGate

Neurological disorders have emerged as a significant global societal burden, exemplified by afflictions like Alzheimer's and Parkinson's, impacting over one billion individuals globally and surpassing the combined economic burden of cancer and diabetes. This has spurred a concerted global effort, with increased support for neuroscience research...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Stochastic Communication Inside Cortical Microcolumns

STOICISM

Neurodegeneration, such as Alzheimer’s disease, currently affects 15 million people in the US with a death rate of 29.5% among 65\ years old and produces a cost around 200 billion dollars per annum. These type of pathologies are caused by neuronal communication failures in multi-scales of the cortical microcolumns. Neuroscience has historically...

Funding Programme
Start Date
End Date
Total Funding
€ 202 681
European Countries Involved

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Structural and biochemical basis of protein amyloid evolution

STAMYEV

Protein misfolding and aggregation into amyloid fibrils is a hallmark of serious diseases such as Alzheimer´s, Familial Amyloidotic Polyneuropathy (FAP) and atherosclerosis. Amyloid fibrils can also be biologically functional. Bacterial and fungal amyloids are proposed to form a prominent protein fold early in evolution. It is unclear why many...

Funding Programme
Start Date
End Date
Total Funding
€ 328 141
European Countries Involved

Structural and biophysical characterisation of insulin receptor and glutamate receptors AMPAR and NMDAR in complex with SorCS coreceptors 1 and 2

SorCS

Type II diabetes (T2D), Alzheimer’s Disease (AD) and Parkinson’s disease (PD) are common age-related diseases, which have reached endemic levels and become a burden for the global health. Lifestyle and environment are risk factors, but cannot explain all cases - genes also predispose for these diseases. Common for T2D, AD and PD is abnormal cell...

Funding Programme
Start Date
End Date
Total Funding
€ 214 934
European Countries Involved

Structure and function of γ-secretase studied by single particle cryo-electron microscopy

γsecretase structure

The γ-secretase intramembrane protease complex plays a critical role in multiple cellular processes including Notch signaling and secretion of amyloid β peptides, the accumulation of which causes Alzheimer’s disease (AD). The enzymatic activity of γ-secretase is, therefore, a prime target for intervention in AD and is of major interest. Yet...

Funding Programme
Start Date
End Date
Total Funding
€ 173 000
European Countries Involved

Study and Identification of ADAM10 as Neuronal α-secretase in relation to Alzheimer’s disease

ADAMNEURON

With life expectancy increasing rapidly in our Western world, Alzheimer’s disease (AD), a progressive neurodegenerative disorder resulting in dementia, is becoming more common, however no cures or effective treatments are currently available. The neurotoxic amyloid-β (Aβ) peptide appears central to AD pathogenesis, and is generated by β- and γ...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Study feasibility and best route to market for telecare solution in Germany and Japan

NASTEX

Navigil has launched a disruptive wearable mobile personal safefy solution into the Finnish market (http://www.navigil.com/products/s1-wearable-telecare-watch-phone/). The solution has been developed using customer requirements from market leading telecare provider (Esperi Care) who is our first customer and from similar entities in the UK. Wearers...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Study of tau strains to understand the phenotypic diversity of Alzheimer’s disease: A step toward personalized therapies

DIVE into AD

Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of dementia cases. However there is still not a single available treatment that modifies the course of disease. Therefore...

Funding Programme
Start Date
End Date
Total Funding
€ 278 841

Study of the aging-related changes of the gamma-secretase complex and evaluation to what extent those contribute to amyloid accumulation in sporadic Alzheimer’s disease

Γ-SECRETASE AGING

Alzheimer’s disease (AD) is the most common form of dementia. The main hallmark of AD is presence of the extraneuronal senile plaques composed of amyloid beta-peptide (Aβ). Aβ is produced when a transmembrane glycoprotein called Amyloid Precursor Protein (APP) is consecutively cleaved by two proteases: the γ-secretase and the β-secretase. γ...

Funding Programme
Start Date
End Date
Total Funding
€ 160 100
European Countries Involved

Study of the interaction between metabolic stress and a specific genetic background on the contribution of sporadic Alzheimer's Disease

T2DM and AD

Different from the familial forms, late onset Alzheimer’s disease (LOAD) is not the consequence of a single cause: neither aging, nor genetic polymorphisms nor an environmental disturbance do, per se, suffice to produce this disease. It is currently thought that instead disease is the consequence of an interaction of all the above circumstances...

Funding Programme
Start Date
End Date
Total Funding
€ 170 122
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).